UK-based specials manufacturer Quantum Pharmaceutical has appointed Andrew Matthews as operations director to maintain high performance standards and develop the business.
Matthews has more than 12 years’ experience in the pharmaceutical and healthcare industries. He has specialist knowledge in product areas for sterile and non-sterile medicines.
Matthews’ experience in quality driven operations management for unlicensed and licensed medicines will assist Quantum Pharmaceutical in its aim of strengthening links with hospitals, care home and home care pharmaceutical providers, as the company broadens its core customer base.
‘Andrew had an excellent CV and great track record as head of manufacturing ‘Specials’ with his former employer, domiciliary care organisation Healthcare At Home,’ said Andy Scaife, md of Quantum Pharmaceutical.
‘With knowledge of this niche sector of the pharmaceutical industry, Andrew is an excellent fit for Quantum but, most importantly, he brings a new skills set which will be of great benefit as we look to exploit new market opportunities.
Quantum Pharmaceutical appoints operations director
Andrew Matthews brings a new set of skills to the company
You may also like
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Portable gas detection in the pharmaceutical sector]()
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
![New legal duties for QPs in decentralised manufacturing]()
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
![FDA escalates action against Dabur India over systemic data-integrity and cGMP failures]()
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies